Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Corridor Pharmaceuticals, Inc. logo — Pioneering the development and commercialization of therapeu...

Corridor Pharmaceuticals, Inc.

Pioneering the development and commercialization of therapeutic inhibitors to combat hyperplasia and fibrosis through innovative small molecule therapies.

Founded 2007 2-10 employees Debt Financing Total: $27.62M Biotechnology, Health Care +1

General Information

Company Name Corridor Pharmaceuticals, Inc.
Founded Year 2007
Employees 2-10
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Corridor Pharmaceuticals, Inc.. To contact Corridor Pharmaceuticals, Inc., visit corridorpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Corridor Pharmaceuticals, Inc. compare?

A PDF of Corridor Pharmaceuticals, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Corridor Pharmaceuticals, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Corridor Pharmaceuticals, Inc.

Corridor Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on developing and commercializing therapeutic small molecule inhibitors of arginase, an enzyme that competes with endothelial nitric oxide synthase for l-arginine, a common substrate. The company's arginase also produces ornithine, which elevates polyamine levels, stimulates cell division, and contributes to hyperplasia and fibrosis. Founded in 2007 and based in Lutherville, Maryland, the company was originally known as Arginetix, Inc., before changing its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. Corridor Pharmaceuticals, Inc. is pioneering the development and commercialization of therapeutic inhibitors to combat hyperplasia and fibrosis through innovative small molecule therapies. The company has received a $1.56M Debt Financing investment on January 31, 2013, demonstrating interest and confidence from the investment community in its potential to make significant strides in the biotechnology and healthcare industries.

Business keywords: Biopharmaceutical, Therapeutic Inhibitors, Small Molecule Therapies, Arginase Inhibitors, Hyperplasia Treatment, Fibrosis Treatment, Enzyme Inhibition, Polyamine Modulation, Cell Division, Biomedical Innovation, L-Arginine Metabolism, Drug Development, Healthcare Research, Biotech Startups, Medical Therapies

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $1.56M -
31 Jan 2013
Series A $13.01M 9
Domain Associates Quaker BioVentures Red Abbey Venture Partners
Domain Associates, Quaker BioVentures +7
24 Jun 2010
Series A $10.75M 1
OUP (Osage University Partners)
02 Oct 2009
Seed Round $2.30M -
23 Oct 2008

Corridor Pharmaceuticals, Inc. Alternatives & Competitors

View All Alternatives
Corridor Pharmaceuticals, Inc. vs
Panacos Pharmaceuticals
Panacos Pharmaceuticals

Innovative solutions in the fight against HIV and other viral diseases using advanced small-molecule...

Post-IPO Debt
Biotechnology, Health Care
Corridor Pharmaceuticals, Inc. vs
Nitrase Therapeutics
Nitrase Therapeutics United States

Pioneering Nitrase Biology and Medicines

Series A
13 employees
Biotechnology, Health Care
Corridor Pharmaceuticals, Inc. vs
Advanced BioDesign
Advanced BioDesign France

Overcoming Tumor Drug Resistance

Venture round
20 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Corridor Pharmaceuticals, Inc.

Pioneering the development and commercialization of therapeutic inhibitors to combat hyperplasia and fibrosis through innovative small molecule therapies.
Corridor Pharmaceuticals, Inc. was founded in 2007.
Corridor Pharmaceuticals, Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Biopharmaceutical, Therapeutic Inhibitors, Small Molecule Therapies and Arginase Inhibitors.
Corridor Pharmaceuticals, Inc. has approximately 2-10 employees.
Corridor Pharmaceuticals, Inc. has completed 4 funding rounds, raising a total of $27.62M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Corridor Pharmaceuticals, Inc. include Panacos Pharmaceuticals, Nitrase Therapeutics, Advanced BioDesign, Incyclix Bio, Flexus Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Corridor Pharmaceuticals, Inc. and Panacos Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Corridor Pharmaceuticals, Inc., https://bouncewatch.com/company/corridor-pharmaceuticals-inc, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout